Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
23.25
-0.22 (-0.94%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Vera Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Vera Therapeutics stock have an average target of 65.5, with a low estimate of 38 and a high estimate of 107. The average target predicts an increase of 181.72% from the current stock price of 23.25.
Analyst Consensus: Buy
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for Vera Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $77 → $71 | Buy | Maintains | $77 → $71 | +205.38% | Mar 4, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $59 → $61 | Strong Buy | Maintains | $59 → $61 | +162.37% | Feb 27, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates $49 | Buy | Initiates | $49 | +110.75% | Feb 4, 2025 |
| Wells Fargo | Wells Fargo | Buy Initiates $70 | Buy | Initiates | $70 | +201.08% | Nov 21, 2024 |
| Wedbush | Wedbush | Hold Maintains $30 → $38 | Hold | Maintains | $30 → $38 | +63.44% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
n/a
from 942.65M
Revenue Next Year
n/a
EPS This Year
-3.21
from -2.75
EPS Next Year
-3.20
from -3.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 197.6M | 323.0M | ||
| Avg | n/a | 62.4M | 195.4M | ||
| Low | n/a | 7.7M | 79.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 417.9% | ||
| Avg | - | - | 213.3% | ||
| Low | - | - | 27.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.54 | -0.51 | -0.11 |
| Avg | -3.21 | -3.20 | -1.96 |
| Low | -3.90 | -4.55 | -3.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.